Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farxiga in Type 2 Diabetes with Moderate Renal Impairment (DERIVE)
NCT02413398Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Jun 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02413398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02413398.